Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2528216 | 0.98 | AGBL2 (0.38) | AGBL2PRMT5WDR77LOXL2ADORA2A | |
| Hydrochloric Acid SCHEMBL18764622 | 0.98 | AGBL2 (0.38) | AGBL2PRMT5WDR77LOXL2ADORA2A | |
| SCHEMBL29877399 | 0.84 | AGBL2 (0.38) | AGBL2ADORA2A | |
| SCHEMBL1396051 | 0.84 | AGBL2 (0.38) | AGBL2ADORA2A | |
| Hydrochloric Acid SCHEMBL3233626 | 0.83 | TDP1 (0.37) | AGBL2 | |
| Hydrochloric Acid SCHEMBL1396013 | 0.83 | TDP1 (0.37) | AGBL2 | |
| SCHEMBL24423846 | 0.78 | AGBL2 (0.37) | AGBL2PRMT5WDR77LOXL2 | |
| SCHEMBL186568 | 0.78 | HTT (0.39) | LOXL2 | |
| SCHEMBL17768622 | 0.78 | AGBL2 (0.37) | AGBL2PRMT5WDR77LOXL2ADORA2A | |
| SCHEMBL13732029 | 0.78 | NOS3 (0.39) | AGBL2PRMT5WDR77LOXL2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | RELAY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2024140968-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-116023380-B | Pyrazolopyrimidine derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-01-23 | — | — | CN | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| WO-2007064619-A1 | PYRIMIDINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007061714-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | AGBL2 2698/4885PRMT5 3036/4885WDR77 809/4885 |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | PIK3CD, PIK3CB, PIK3R1 | AGBL2 1302/4885PRMT5 1713/4885WDR77 3531/4885 |
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | AGBL2 3779/4885PRMT5 787/4885WDR77 230/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | AGBL2 601/4885PRMT5 1996/4885WDR77 2806/4885 |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | AGBL2 429/4885PRMT5 2111/4885WDR77 3450/4885 |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ROCK1, ROCK2, RHOA | AGBL2 784/4885PRMT5 692/4885WDR77 1241/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | AGBL2 4169/4885PRMT5 1887/4885WDR77 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.